CIEMAT Madrid CRISPR Seminar - 8 June @ 12 CEST

A CRISPR Seminar focusing on the editing of Stem Cells (iPSCs and HSC) including a case story presented by CIEMAT Madrid: New Gene Editing Strategies to Correct Hematopoietic Stem Cells in Fanconi Anemia Patients

CRISPR/Cas9 editing has vastly expanded our capabilities to precise engineer the genome. However, the editing efficiencies for different cell lines and types can vary widely and often makes the workflow incredibly laborious. Synthego has developed a robust, automated CRISPR-editing process that delivers consistently high editing in virtually any cell type. This expertise has been applied to immortalized cell lines and iPSCs editing to achieve unprecedented editing efficiencies of the highest quality. Register today to learn how to plan & optimize your CRISPR experiments and how to reach higher editing efficiencies in stem cells & difficult cells.

Dr. Nadia Tagnaouti will start the seminar with a general CRISPR overview covering: 

  • Design and Optimization for successful CRISPR KO/KI experiments 
  • Novel multiguide design for higher KO scores & reproducible results
  • Tips and tricks to move from single-digit editing efficiency to 90% efficiencies in Stem Cells/iPSCs

Our special guest, Laura Ugalde Díaz from CIEMAT-Madrid will cover the second part of the webinar. Laura will show us how she successfully implemented CRISPR tools to correct Hematopoietic Stem Cells (HCS) in Fanconi Anemia patients (FA). Fanconi Anemia is an inherited genetic disorder caused by mutations in any of the 22 genes that constitute the DNA damage response FA/BRCA pathway, which altered function results in genomic instability. The primary pathological feature during the first decade of life is the appearance of hematological defects that leads to BM failure, the main cause of mobility and mortality in pediatric patients. Allogeneic hematopoietic stem cell (HSC) transplantation is currently the only curative treatment for bone marrow failure in FA patients. Laura will be presenting the development of new gene-editing technologies for promising alternatives to correct the patients' HSCs.

More info on the registration site